TLR2 and breast carcinoma: In the case of TLR-2 and HVEM, the median plasma levels of these two biomarkers were significantly lower in early breast cancer patients compared to those of healthy controls these being 24059.42 vs. 30477.20 pg/mL, p<0.0141 and 1866.92 vs. 2290.19 pg/mL, p<0.0001, respectively.